MAPS is a 501(c)(3) non-profit pharmaceutical company working with the FDA and international regulatory agencies to develop psychedelics and marijuana into prescription medicines for patients with unmet medical needs.
Since its founding in 1986, MAPS has disbursed over $12 million to research and education surrounding the potential therapeutic uses of psychedelics and marijuana. MAPS is now funding or coordinating clinical trials of MDMA-assisted psychotherapy for PTSD in eight countries around the world. Our headquarters is located in Santa Cruz, California.
Donations are tax-deductible for U.S. citizens. Our federal tax identification number is 59-2751953.
For more information, visit www.maps.org.